SCHEMBL15682811

SCHEMBL15682811

NNC(=O)C(=O)NCc1cccc(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 1/20 0.53
▸ GABRD O14764 1/20 0.53
▸ GABRA1 P14867 1/20 0.53
▸ GABRB1 P18505 1/20 0.53
▸ GABRG2 P18507 1/20 0.53
▸ GABRB3 P28472 1/20 0.53
▸ GABRA5 P31644 1/20 0.53
▸ GABRA3 P34903 1/20 0.53
▸ GABRA2 P47869 1/20 0.53
▸ GABRB2 P47870 1/20 0.53
▸ GABRA4 P48169 1/20 0.53
▸ GABRE P78334 1/20 0.53
▸ GABRA6 Q16445 1/20 0.53
▸ GABRG1 Q8N1C3 1/20 0.53
▸ GABRG3 Q99928 1/20 0.53
▸ GABRQ Q9UN88 1/20 0.53
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ APEX1 P27695 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25780410 0.85 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL626329 0.81 CYP2C9 (0.62) NPC1RAB9AHDAC1
SCHEMBL15682780 0.81 SRC (0.52) RAB9A
SCHEMBL17235930 0.81 KMT2A (0.51) NPC1RAB9A
SCHEMBL3552958 0.80 RXFP1 (0.59) NPC1RAB9ARXFP1APEX1
SCHEMBL17235945 0.80 CYP2C9 (0.65) NPC1RAB9A
SCHEMBL11126187 0.79 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL881512 0.79 KMT2A (0.61) NPC1RAB9A
SCHEMBL24322980 0.79 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL20697806 0.78 CNR2 (0.51) HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914575-B1 PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF UNIV MICHIGAN REGENTS (US) 2020-10-14 — — EP disclosed
US-20170291893-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF EASTERN MICHIGAN UNIVERSITY 2017-10-12 — — US disclosed
US-9718760-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-01 — — US disclosed
US-20150315178-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-11-05 — — US disclosed
WO-2014070983-A1 PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291893-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF SERPINE1, PLAT, SERPINC1 GABRP 3527/4885GABRD 4814/4885GABRA1 4275/4885
US-20150315178-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF SERPINE1, PLAT, SERPINC1 GABRP 3527/4885GABRD 4814/4885GABRA1 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback